Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Hilma J Van Der Horst, MSc, A. Vera de Jonge, Ida H Hiemstra, PhD, Anne T Gelderloos, MSc, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Prof Dr, Martine E.D. Chamuleau, Sonja Zweegman, MD PhD, Esther CW Breij, DPhil, Margaretha GM Roemer, PhD, Tuna Mutis

Blood (2019) 134 (Supplement_1): 4066.

https://doi.org/10.1182/blood-2019-125765

Published: 2019

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD

Blood (2017) 130 (Supplement 1): 1835.

https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835

Published: 2017

NARROW

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Email alerts

ASH Publications

American Society of Hematology

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only